KDR

(redirected from CD309)

KDR

A gene on chromosome 4q11-q12 that encodes a vascular endothelial growth factor receptor known as kinase insert domain receptor, which is a type-III receptor tyrosine kinase. KDR is the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting.

Molecular pathology
KDR mutations have been linked to infantile capillary haemangiomas.
Mentioned in ?
References in periodicals archive ?
Marker Fluorochrome Host Clone CD14 PE Mouse anti-human M[phi]P9 CD16 FITC Mouse anti-human B73.1 CD34 FITC Mouse anti-human 581 CD45 PE Mouse anti-human HI30 CD133 APC Mouse anti-human AC133 CD235a FITC Mouse anti-human GA-R2 (HIR2) CD309 PE Mouse anti-human 89,106 Marker Manufacturer CD14 Becton Dickinson Bioscience CD16 Becton Dickinson Bioscience CD34 Becton Dickinson Bioscience CD45 Becton Dickinson Bioscience CD133 Miltenyi Biotec CD235a Becton Dickinson Bioscience CD309 Becton Dickinson Bioscience PE: phycoerythrin; FITC: fluorescein isothiocyanate; APC: allophycocyanin.
Cell origin of microvesicles was determined using lineage specific antigen labeling with CD105 AF647 (BD Biosciences), platelet and endothelial cell adhesion molecule 1 (PECAM1)/CD31 BV510 (BD Biosciences), VEGFR2/ CD309 AF647 (BD Biosciences), and mucosal vascular addressin cell adhesion molecule 1/MadCAM APC (Biotechne R&D Systems).
The next most manifest response was the level of expression of CD309 (VEGFR-2), which is known to increase endothelial permeability in microvascular bed [45].
An increase in CD309 expression leads to increase of endothelial permeability in microvascular bed [45].
Mononuclear cells (5 x [10.sup.6]) were labeled with preconjugated mouse anti-human monoclonal antibodies: CD34 conjugated to allophycocyanin, CD309 (VEGF receptor-2 [VEGFR2]/kinase insert domain-containing receptor [KDR]) to fluorescein isothiocyanate (BD Biosciences, USA), and CD45 to peridinin chlorophyll protein-cyanine for 20 min at room temperature.
C, Negative control, and D, cells co-expressing CD34 and CD309 were designated as cEPCs.
For analysis of endothelial progenitor cells (EPCs), fresh whole blood EDTA-anticoagulated samples (100 [micro]L) were incubated for 30 minutes at room temperature with the following monoclonal antibodies: 20 [micro]L of FITC anti-human CD34, 5 [micro]L of PE anti-human CD144 (VE-cadherin), or 5 [micro]L of PE antihuman CD309 (VEGFR-2) (BD PharMingen, Erembodegen, Belgium).
MSCs do not express CD31, CD144, and CD309 (endothelial cell markers) or CD14, CD34, CD45, CD117, and CD133 (hematopoietic cell markers) [61, 79].
The human KDR gene, for example, has been known by many different symbols (e.g., VEGFR2, CD309, FLK1, VEGFR).
BFP-DFAT cells have been shown to be positive for CD90, CD105 [14], CD13, CD29, and CD44 [15] but negative for CD11b (monocyte marker), CD34 (hematopoietic progenitor cell marker), CD45 (leukocyte common antigen) [14], CD31, CD309, CD106, and alpha-smooth muscle actin [15, 30].